Luceron-Lucas-Torres M, Ruiz-Grao M, Pascual-Morena C, Priego-Jimenez S, Lopez-Gonzalez M, Alvarez-Bueno C
Alcohol Alcohol. 2025; 60(2).
PMID: 39950360
PMC: 11826089.
DOI: 10.1093/alcalc/agaf004.
Longwill O
Cureus. 2024; 16(10):e71199.
PMID: 39525239
PMC: 11549845.
DOI: 10.7759/cureus.71199.
Huang Z, Yao J, Nie L, Nie X, Xiong X, Koks S
J Headache Pain. 2024; 25(1):175.
PMID: 39390364
PMC: 11468534.
DOI: 10.1186/s10194-024-01875-3.
Bano F, Alkhayl F, Rashid M, Alqethami M, Alsufyani M, Alhothali K
CNS Neurol Disord Drug Targets. 2024; 24(3):219-233.
PMID: 39279695
DOI: 10.2174/0118715273306929240820071521.
Amendolara A, Magoffin W, Naik A, Sant D, Kriak J, Green B
Cureus. 2024; 16(2):e54987.
PMID: 38550449
PMC: 10973797.
DOI: 10.7759/cureus.54987.
Novel FDA-approved zavegepant drug for treating migraine.
Ahmed U, Saleem M, Osman M, Shamat S
Ann Med Surg (Lond). 2024; 86(2):923-925.
PMID: 38333255
PMC: 10849432.
DOI: 10.1097/MS9.0000000000001620.
Efficacy and safety of eptinezumab for migraine: A systematic review and meta-analysis.
Zhong Y, Wang J, Li H, Yang S, Li X, Gao H
J Res Med Sci. 2024; 28:82.
PMID: 38292336
PMC: 10826853.
DOI: 10.4103/jrms.jrms_306_22.
The physical impact of migraines on female chiropractic patients: A qualitative study.
Pirthiraj A, Bhagwan R
Health SA. 2023; 28:2283.
PMID: 37927942
PMC: 10623481.
DOI: 10.4102/hsag.v28i0.2283.
Migraine: Advances in the Pathogenesis and Treatment.
Ples H, Florian I, Timis T, Covache-Busuioc R, Glavan L, Dumitrascu D
Neurol Int. 2023; 15(3):1052-1105.
PMID: 37755358
PMC: 10535528.
DOI: 10.3390/neurolint15030067.
Association between brain structures and migraine: A bidirectional Mendelian randomization study.
Guo X, Wang D, Ying C, Hong Y
Front Neurosci. 2023; 17:1148458.
PMID: 36937660
PMC: 10020331.
DOI: 10.3389/fnins.2023.1148458.
Prediction and associated factors of non-steroidal anti-inflammatory drugs efficacy in migraine treatment.
Lu Z, Dong B, Wei H, Chen L
Front Pharmacol. 2022; 13:1002080.
PMID: 36532762
PMC: 9754055.
DOI: 10.3389/fphar.2022.1002080.
Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults.
Berger A, Keefe J, Stark C, Moore M, Ramirez G, Cucarola J
Health Psychol Res. 2022; 10(5):38439.
PMID: 36381178
PMC: 9662608.
DOI: 10.52965/001c.38439.
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis.
Wang X, Wen D, He Q, You C, Ma L
J Headache Pain. 2022; 23(1):105.
PMID: 36071388
PMC: 9454201.
DOI: 10.1186/s10194-022-01472-2.
Small Demyelination of the Cortex May Be a Potential Marker for the Right-to-Left Shunt of the Heart.
Huo J, Wan M, Li N, Wang J, Cai X, Fan D
Brain Sci. 2022; 12(7).
PMID: 35884691
PMC: 9312883.
DOI: 10.3390/brainsci12070884.
Association between patent foramen ovale and migraine without aura: a community-based cross-sectional study in China.
Tang Y, Peng A, Peng B, He S, Zhao X, Zhu Y
BMJ Open. 2022; 12(3):e056937.
PMID: 35361647
PMC: 8971771.
DOI: 10.1136/bmjopen-2021-056937.
Migraine and Stroke: In Search of Shared Pathways, Mechanisms, and Risk Factors.
Hassan M, Belavadi R, Gudigopuram S, Raguthu C, Gajjela H, Kela I
Cureus. 2021; 13(12):e20202.
PMID: 34900505
PMC: 8647778.
DOI: 10.7759/cureus.20202.
Patients and general practitioners assessment of the main outcomes employed in the acute and preventive treatment of migraine: a cross sectional study.
Trigo-Lopez J, Guerrero-Peral A, Sierra A, Martinez-Pias E, Gutierrez-Sanchez M, Huzzey E
BMC Neurol. 2021; 21(1):279.
PMID: 34261459
PMC: 8281698.
DOI: 10.1186/s12883-021-02220-w.
Peripheral Neuromodulation for the Management of Headache.
Urits I, Schwartz R, Smoots D, Koop L, Veeravelli S, Orhurhu V
Anesth Pain Med. 2021; 10(6):e110515.
PMID: 34150578
PMC: 8207880.
DOI: 10.5812/aapm.110515.
Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis.
Wang X, Chen Y, Song J, You C
Front Pharmacol. 2021; 12:649143.
PMID: 33867991
PMC: 8045977.
DOI: 10.3389/fphar.2021.649143.
Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels.
Kleeberg-Hartmann J, Vogler B, Messlinger K
J Headache Pain. 2021; 22(1):23.
PMID: 33849430
PMC: 8042690.
DOI: 10.1186/s10194-021-01235-5.